trending Market Intelligence /marketintelligence/en/news-insights/trending/wushtof-gagt-swn4qdbmq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Innovus secures rights to allergy drug in US, Canada

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Innovus secures rights to allergy drug in US, Canada

Innovus Pharmaceuticals Inc. secured a contract to market NTC Srl's Lertal tablets in U.S. and Canada under the AllerVarx brand name.

Innovus is making an undisclosed up-front payment to the Italian company and has agreed to make further milestone-related payments as a result of the agreement.

Lertal is used for the treatment of allergic rhinitis.